Quick Read Direxion Daily S&P Biotech Bull 3X Shares (LABU) delivered 235% returns over the past year versus 65% for the ...

Thanks to some favorable news from the Food and Drug Administration (FDA) and more mergers and acquisitions activity, biotechnology stocks and exchange traded are shaking off their previously ...

Seeking Alpha Quant rates LABU as a strong Sell, but I rates it as a Buy due to bullish market conditions. LABU is a leveraged ETF that seeks to track 3x the daily performance of the S&P Biotechnology ...

Biotech stocks have pulled back and offer better risk to reward for investors, Direxion Daily S&P Biotech Bull 3x Shares ETF is a popular way to trade them. M&A is likely to drive prices for mid-cap ...

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, ...

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...

Sean Ross is a strategic adviser at 1031x.com, Investopedia contributor, and the founder and manager of Free Lances Ltd. The Direxion Daily S&P Biotech Bull 3X Fund (NYSEARCA: LABU) is an exchange ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...